Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Verseon presents new efficacy results on oral diabetic macular edema drug candidate at vision and ophthalmology conference

Posted on: 02 May 18

Fremont, Calif.—Verseon presented new efficacy results on its diabetic macular edema drug candidates at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting in Honolulu this week. The preclinical data show that Verseon’s oral plasma kallikrein inhibitors successfully reduce retinal thickness and retinal leakage, two hallmarks of the disease.

Diabetic macular edema (DME) is a leading cause of blindness in today’s growing diabetic population. In diabetics, chronically high blood sugar can weaken blood vessels in the eye and cause fluids to leak. Fluid accumulating in the macula (the central region of the retina responsible for keenest vision) can result in swelling, blurred vision, and eventually central vision loss. The current standard of care for DME includes regular injections into the eye of repurposed anticancer agents or corticosteroids, treatments associated with side effects such as inflammation and infection.

At ARVO, Verseon’s Dr. Melissa Calton presented comprehensive preclinical data for one of Verseon’s new, potent and selective small-molecule plasma kallikrein inhibitors, VE-3539. In contrast to current DME drugs, Verseon’s compound shows pharmacokinetics suitable for oral administration. Results from a well-established efficacy model, the retinal vascular permeability model, show that VE‑3539 successfully reduces retinal leakage and restores mean circulation times. “VE-3539 is the first orally dosed plasma kallikrein inhibitor to demonstrate efficacy in this preclinical model of DME,” said Dr. Calton. Additionally, Verseon’s candidate is efficacious in another widely used model of DME, the human plasma kallikrein injection model, that mimics the retinal thickening observed in patients.

“Verseon’s DME drugs could offer a safe and convenient alternative to intravitreal injections,” said Dr. Calton. “With their oral route of administration, our drug candidates are especially well-suited for prophylaxis, providing an important benefit for the growing number of diabetics who are at risk of losing their eye sight through DME.”

Verseon uses a computer-driven drug discovery platform embedded in a comprehensive chemistry and biology workflow to design new drug candidates for a wide range of diseases. In addition to the diabetic macular edema program, the company currently has drug programs in anticoagulation, hereditary angioedema, and oncology.

About Verseon’s diabetic macular edema program

Verseon has developed a new class of potent, selective compounds for the treatment of diabetic macular edema. The Company’s plasma kallikrein inhibitors target a validated pathway addressing an underlying cause of the disease. In contrast to current injectable DME drugs, Verseon’s inhibitors show pharmacokinetics suitable for oral administration in preclinical testing. Several lead candidates have also demonstrated efficacy in reducing retinal thickening and retinal leakage, two hallmarks of the disease, when administered orally.

About Verseon

Verseon Corporation (, AIM: VSN) is a technology-based pharmaceutical company that pairs a proprietary, computational drug discovery platform with a comprehensive in-house chemistry and biology workflow to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology. The anticoagulation program is scheduled to enter phase I clinical trials in 2018.


For further information please contact:

Verseon Corporation—Tina Schlafly

+1 (510) 225 9014


For trade and pharma media enquiries please contact:

Vane Percy & Roberts—Simon Vane Percy

+44 (0) 1737 821 890

Editor's Details

Mike Wood

Last updated on: 02/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.